Methodological issues in primary prevention trials for neurodegenerative dementia.
about
MAPT STUDY: A MULTIDOMAIN APPROACH FOR PREVENTING ALZHEIMER'S DISEASE: DESIGN AND BASELINE DATA.Consequences from use of reminiscence--a randomised intervention study in ten Danish nursing homes.Study of Mental Activity and Regular Training (SMART) in at risk individuals: a randomised double blind, sham controlled, longitudinal trialIntegrating ADNI results into Alzheimer's disease drug development programs.Report of the task force on designing clinical trials in early (predementia) AD.Is hyperhomocysteinemia an Alzheimer's disease (AD) risk factor, an AD marker, or neither?A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease.Prevention strategies for Alzheimer's disease.Diet and neurocognition: review of evidence and methodological considerations.Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment.Should interventions to treat or prevent Alzheimer's disease be tested in a population or as targeted treatment of highly selected study participants?Recruitment methods for United States Alzheimer disease prevention trials.Determinants of Dropout and Nonadherence in a Dementia Prevention Randomized Controlled Trial: The Prevention of Dementia by Intensive Vascular Care Trial.Prevalence and conversion to dementia of Mild Cognitive Impairment in an elderly Italian population.The world of dementia beyond 2020.EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia.
P2860
Q31027253-8788F10A-91DE-4394-82BE-02FE1CA07FC5Q33595407-4C0C7E22-BB8D-4A4E-AB79-21EA84A3D74BQ33879103-F21AB641-6932-47CE-97B1-DBFB8748EC52Q33987409-D8FB559C-D868-4C86-8B81-36580DF0EE02Q34555301-F5535CD0-C660-45AD-8E14-ECE87335F4AAQ35175404-F93949DD-7179-4709-A122-0AB6508050F5Q35879102-E0919558-E2CD-40CF-896A-F540B59804B4Q36444462-69BA5D14-8F71-4A52-8B8D-6778AF0914F7Q36655203-CDF1C7FB-9B90-4E8F-BC1C-BE5ECB4305E3Q36998758-FED37CC7-564B-42F4-BAA8-D875877A749DQ37690944-4314A9A8-852F-4D9C-AC44-E81CD0FD8E20Q38002365-AAEF0981-E57E-4D01-882C-2434C49B6CDFQ38750156-3B221C65-B171-48A7-ACCB-916E89FC247AQ38869538-A63D07B5-9090-4539-B642-EE220E22CCA3Q39761109-6C35066D-8190-42FE-A84E-995097261287Q45289583-EBEC5FF9-9638-47DB-8F0F-5BAFF13A97E7
P2860
Methodological issues in primary prevention trials for neurodegenerative dementia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Methodological issues in primary prevention trials for neurodegenerative dementia.
@en
Methodological issues in primary prevention trials for neurodegenerative dementia.
@nl
type
label
Methodological issues in primary prevention trials for neurodegenerative dementia.
@en
Methodological issues in primary prevention trials for neurodegenerative dementia.
@nl
prefLabel
Methodological issues in primary prevention trials for neurodegenerative dementia.
@en
Methodological issues in primary prevention trials for neurodegenerative dementia.
@nl
P2093
P50
P356
P1476
Methodological issues in primary prevention trials for neurodegenerative dementia.
@en
P2093
Frans Verhey
Gordon Wilcock
Howard Fillit
Jane Durga
Jean-Marc Orgogozo
Linus Jönsson
Lutz Froelich
Philippe Robert
Pierre-Jean Ousset
P304
P356
10.3233/JAD-2009-0971
P50
P577
2009-01-01T00:00:00Z